Cowen and Company started coverage on shares of Akcea Therapeut (NASDAQ:AKCA) in a report issued on Tuesday, Marketbeat reports. The brokerage issued an outperform rating on the stock.

Separately, Stifel Nicolaus assumed coverage on Akcea Therapeut in a research report on Tuesday. They issued a buy rating and a $19.00 price objective for the company.

Akcea Therapeut (NASDAQ:AKCA) traded down 1.77% during midday trading on Tuesday, reaching $14.44. 211,100 shares of the company were exchanged. The company has a 50 day moving average of $9.93 and a 200-day moving average of $9.93. The company’s market capitalization is $927.02 million. Akcea Therapeut has a 52-week low of $1.05 and a 52-week high of $16.30.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Begins Coverage on Akcea Therapeut (NASDAQ:AKCA)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/09/cowen-and-company-begins-coverage-on-akcea-therapeut-nasdaqakca.html.

In other Akcea Therapeut news, major shareholder Ionis Pharmaceuticals Inc acquired 3,125,000 shares of the business’s stock in a transaction on Wednesday, July 19th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $25,000,000.00. Following the completion of the transaction, the insider now owns 28,884,540 shares of the company’s stock, valued at approximately $231,076,320. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

About Akcea Therapeut

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Receive News & Ratings for Akcea Therapeut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeut and related companies with MarketBeat.com's FREE daily email newsletter.